Synthesis and validation of DOPY: A new gemini dioleylbispyridinium based amphiphile for nucleic acid transfection

dc.contributor.authorAubets Gil, Eva
dc.contributor.authorGriera Farres, Rosa
dc.contributor.authorFélix, Álex J.
dc.contributor.authorRigol Pujol, Gemma
dc.contributor.authorSikorski, Chiara
dc.contributor.authorLimón Magaña, David
dc.contributor.authorMastrorosa, Chiara
dc.contributor.authorBusquets i Viñas, Ma. Antonia
dc.contributor.authorPérez García, M. Lluïsa (Maria Lluïsa)
dc.contributor.authorNoé Mata, Verónica
dc.contributor.authorCiudad i Gómez, Carlos Julián
dc.date.accessioned2022-01-12T08:03:45Z
dc.date.available2022-12-31T06:10:25Z
dc.date.issued2021
dc.date.updated2022-01-12T08:03:45Z
dc.description.abstractNucleic acids therapeutics provide a selective and promising alternative to traditional treatments for multiple genetic diseases. A major obstacle is the development of safe and efficient delivery systems. Here, we report the synthesis of the new cationic gemini amphiphile 1,3-bis[(4-oleyl-1-pyridinio)methyl]benzene dibromide (DOPY). Its transfection efficiency was evaluated using PolyPurine Reverse Hoogsteen hairpins (PPRHs), a nucleic acid tool for gene silencing and gene repair developed in our laboratory. The interaction of DOPY with PPRHs was confirmed by gel retardation assays, and it forms complexes of 155 nm. We also demonstrated the prominent internalization of PPRHs using DOPY compared to other chemical vehicles in SH-SY5Y, PC-3 and DF42 cells. Regarding gene silencing, a specific PPRH against the survivin gene delivered with DOPY decreased survivin protein levels and cell viability more effectively than with N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) in both SH-SY5Y and PC-3 cells. We also validated the applicability of DOPY in gene repair approaches by correcting a point mutation in the endogenous locus of the dhfr gene in DF42 cells using repair-PPRHs. All these results indicate both an efficient entry and release of PPRHs at the intracellular level. Therefore, DOPY can be considered as a new lipid-based vehicle for the delivery of therapeutic oligonucleotides.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec713490
dc.identifier.issn0939-6411
dc.identifier.urihttps://hdl.handle.net/2445/182280
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1016/j.ejpb.2021.05.016
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2021, vol. 165, p. 279-292
dc.relation.urihttps://doi.org/10.1016/j.ejpb.2021.05.016
dc.rightscc-by (c) Eva Aubets Gil, et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
dc.subject.classificationCàncer
dc.subject.classificationTeràpia genètica
dc.subject.classificationExpressió gènica
dc.subject.otherCancer
dc.subject.otherGene therapy
dc.subject.otherGene expression
dc.titleSynthesis and validation of DOPY: A new gemini dioleylbispyridinium based amphiphile for nucleic acid transfection
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
713490.pdf
Mida:
5.82 MB
Format:
Adobe Portable Document Format